Wegovy recommendations from NICE and the NHS: the real picture

The myth that NICE's recommendation means Wegovy is freely available on the NHS

A question our prescribers hear most weeks goes something like this: "NICE approved it in 2023, so why can't my GP prescribe it?" It's a fair frustration, and the answer lies in what NICE's recommendation actually does and doesn't do. NICE's Technology Appraisal 875 found Wegovy cost-effective, but specifically within specialist weight management services with full multidisciplinary support. That structure includes dietitians, psychological input and sustained follow-up. Most GP practices don't have that in-house, so the standard NICE route runs through specialist referral rather than routine GP prescribing.

NHS England has been rolling out a separate, phased scheme for tirzepatide (Mounjaro) in primary care, but Wegovy's NHS route remains the specialist-service pathway. The result is that waiting lists in many parts of England are long. NICE recommending a treatment and that treatment being accessible within a reasonable timeframe are two different things. That gap is where private prescribing becomes a practical alternative for people who are clinically suitable but can't or would rather not wait.

For a plain account of how the NHS and private routes sit alongside each other, the weight-loss treatment overview covers both without overstating either.

Who the NICE criteria actually apply to

NICE TA875 sets out specific eligibility conditions for Wegovy on the NHS. Adults need a BMI of 35 or above and at least one weight-related condition such as type 2 diabetes, high blood pressure, obstructive sleep apnoea or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, that BMI threshold is typically set 2.5 kg/m² lower, in line with UK guidance on ethnicity-adjusted thresholds. NHS England quotes 32.5 as the adjusted starting point rather than 35.

Crucially, NICE also specifies that Wegovy should only be used for a maximum of two years in this NHS context, alongside a reduced-calorie diet and increased physical activity. If someone hasn't lost at least 5% of their body weight after six months at the maintenance dose, the guidance says continuing treatment should be reviewed. These conditions are part of the economic case NICE accepted; they don't apply in the same way to a private prescription, where the licensed SmPC criteria govern instead.

Private eligibility follows the Wegovy licence: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. A prescriber still makes the individual call, the lower BMI threshold in the licence opens the door, but it doesn't guarantee approval. You can read about the private route for Wegovy in more detail, including what a clinical assessment covers.

What the NICE recommendation says about how Wegovy should be used

Beyond eligibility, NICE TA875 specifies the care context. Treatment should sit within a specialist weight management service that can provide multidisciplinary support, not simply a medicine handed over at a pharmacy counter. The two-year duration cap reflects both the trial evidence base and the cost model NICE used. It's worth noting that this cap exists in the NHS recommendation; it is not a statement that Wegovy stops working or becomes unsafe after two years. Clinical judgement still applies, and prescribers can review individual circumstances.

The NICE guidance also flags that stopping treatment typically leads to weight regain, which is consistent with how the medicine works physiologically. None of this is buried in small print: the NICE TA875 guidance is publicly available and worth reading if you want the full detail. For questions about surgical procedures and what to tell your team if you're taking Wegovy, the Wegovy and operations page covers the practical points prescribers advise on.

How private prescribing sits alongside the NICE framework

Private prescribing operates under the Wegovy marketing authorisation granted by the MHRA, not under NICE's NHS-specific appraisal. The SmPC criteria are broader: BMI 30 or above, or 27 to 29.9 alongside a weight-related condition. A GPhC-registered independent prescriber reviews each case, medical history, current medicines, contraindications and whether the treatment is appropriate for that individual. At nume, every consultation is read by a clinician the same day it's submitted; your answers go to a prescriber's desk, not through an automated filter.

Side effects and safety considerations don't change between NHS and private routes, they're determined by the medicine itself. The most common are gastrointestinal: nausea, loose stools, constipation and reflux are frequently reported, particularly in the early weeks and after dose increases. A full breakdown is on the Wegovy side effects page, including the symptoms that warrant prompt medical attention. Where you source treatment does affect whether you have a prescriber to contact when those questions come up. At nume, aftercare support is available seven days a week, and if you'd like to know which wegovy locations we serve near you, that information is easy to find. If you're also unsure how to get to us, our page on getting directions to our pharmacy has everything you need. If you'd like to find out whether you meet the criteria for a private prescription, checking your eligibility takes a few minutes and is free.